The effect of L-arginine supplementation in patients with congestive heart failure

The effect of L-Arginine supplementation on the levels of glucose, N-Terminal pro Brain Natriuretic Peptide (NT pro-BNP), lipids, blood pressure, ejection fraction, quality of life and rehabilitation in patients with congestive heart failure.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170202032367N4

Enrollment

Registered

2019-12-18

Start date

2018-10-23

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congestive heart failure. Systolic (congestive) heart failure

Interventions

Intervention 1: Intervention group: L-Arginine supplement (3 g / day) after breakfast, lunch, dinner for 10 weeks.take it orally and this supplement produced by Karen company. Intervention 2: Placebo

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 35-60 years Diagnosis of ischemic heart failure Ejection fraction less than 40% (based on echocardiography test) Cardiac functional level of 2 or 3 based on the classification of the New York heart association

Exclusion criteria

Exclusion criteria: Kidney, liver or inflammatory bowel diseases, malignancies, thyroid disorders Pregnancy and lactation Taking any dietary supplement including L-arginine within the past 2 months prior to the initiation of the study History of angina pectoris, myocardial infarction or stroke, untreated arrhythmias Taking medications including glucocorticoids, antiarrhythmic or chemotherapy agents, NSAIDs, diltiazem, verapamil, thiazolidinedione Unable to perform 6 minute walking test

Design outcomes

Primary

Measure	Time frame
Serum Triglyceride. Timepoint: Before and after of intervention. Method of measurement: Enzymatic method with auto analyzer- mg/dl.;Serum Total cholestrol. Timepoint: Before and after of intervention. Method of measurement: Enzymatic method with auto analyzer- mg/dl.;Serum Low Density Lipoprotein Cholestrol ( LDL-C ). Timepoint: Before and after of intervention. Method of measurement: Calculate according to fridval formula - mg/dl.;Serum High Density Lipoprotein Cholestrol ( HDL-C. Timepoint: Before and after of intervention. Method of measurement: Enzymatic method with autoanalyzer- mg/dl.;N-terminal pro brain natriuretic peptide. Timepoint: Before and after of intervention. Method of measurement: ELISA.;Fasting Blood Sugar. Timepoint: Before and after of intervention. Method of measurement: Glucose oxidase.;The Minnesota Quality of Life Questionnaire. Timepoint: Before and after of intervention. Method of measurement: questionnaire.;Left ventricular ejection fraction. Timepoint: Before and after of intervention. Method of measurement: Left ventricular EF percentage for echocardiography.;Systolic blood pressure. Timepoint: Before and after of intervention. Method of measurement: Digital sphygmomanometer.;Diastolic blood pressure. Timepoint: Before and after of intervention. Method of measurement: Digital sphygmomanometer.;Distance traveled on 6 minute walk test. Timepoint: Before and after of intervention. Method of measurement: Distance walked in 6 minutes (standard walking route).	—

Measure

Time frame

Serum Triglyceride. Timepoint: Before and after of intervention. Method of measurement: Enzymatic method with auto analyzer- mg/dl.;Serum Total cholestrol. Timepoint: Before and after of intervention. Method of measurement: Enzymatic method with auto analyzer- mg/dl.;Serum Low Density Lipoprotein Cholestrol ( LDL-C ). Timepoint: Before and after of intervention. Method of measurement: Calculate according to fridval formula - mg/dl.;Serum High Density Lipoprotein Cholestrol ( HDL-C. Timepoint: Before and after of intervention. Method of measurement: Enzymatic method with autoanalyzer- mg/dl.;N-terminal pro brain natriuretic peptide. Timepoint: Before and after of intervention. Method of measurement: ELISA.;Fasting Blood Sugar. Timepoint: Before and after of intervention. Method of measurement: Glucose oxidase.;The Minnesota Quality of Life Questionnaire. Timepoint: Before and after of intervention. Method of measurement: questionnaire.;Left ventricular ejection fraction. Timepoint: Before and after of intervention. Method of measurement: Left ventricular EF percentage for echocardiography.;Systolic blood pressure. Timepoint: Before and after of intervention. Method of measurement: Digital sphygmomanometer.;Diastolic blood pressure. Timepoint: Before and after of intervention. Method of measurement: Digital sphygmomanometer.;Distance traveled on 6 minute walk test. Timepoint: Before and after of intervention. Method of measurement: Distance walked in 6 minutes (standard walking route).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahnaz Salmani

Tehran University of Medical Sciences

mahnazsalmani1990@gmail.com+98 21 7748 9968

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026